5

10

ABSTRACT

A compound selected from those of formula (I):

$$(R_a)_m \xrightarrow{A} (Z_1)_n \xrightarrow{Y} 0 \xrightarrow{N} R_3$$
 (I)

in which:

W represents N or C-R₁; in which R₁ is as defined in the description,

X represents N or C-R2 in which R2 is as defined in the description,

Y represents a group selected from oxygen, sulfur, -NH, and -Nalkyl,

 $\label{eq:Z} Z \ represents \ a \ group \ selected \ from \ oxygen, sulphur, -NR_8 \ in \ which \ R_8 \ is \ as \ defined \ in \ the \ description, and optionally carbon depending the definition of \ Y,$

n is an integer from 0 to 8 inclusive,

 Z_1 represents a group $-CR_9R_{10}$ wherein R_9 and R_{10} , are as defined in the description, which group contains optionally multiple bonds or heteroatomes,

A represents a cyclic group,

m is an integer from 0 to 7 inclusive,

15 the group(s) R₄ is (are) as defined in the description,

 R_3 represents a group selected from hydrogen, alkyl, alkenyl, alkynyl, and the group of formula:

$$(\mathbf{Z}_1)_{\mathbf{q}}$$
 $(\mathbf{Z}_2)_{\mathbf{p}}$

in which p, Z₂, B, q, and R₁₃ are as defined in the description,

20 optionally, its racemic forms, isomers thereof, N-oxydes thereof, and its the pharmaceutically acceptable salts thereof, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix mettaloprotease.